PepGen Inc. (PEPG) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
PepGen Inc.
Address
321 Harrison Avenue
Boston, MA 02118
United States of America (the)
Phone
781-797-0979
Website
Sector
Healthcare
Industry
Biotechnology
Employees
57
First IPO Date
May 06, 2022
Key Executives
| Name | Title | Pay | Year Born |
| James G. McArthur | President, Chief Executive Officer, Treasurer, Secretary & Director | 1.06M | 1962 |
| Paul D. Streck | Executive Vice President and Head of Research & Development | 332,733 | 1964 |
| Joseph D. Vittiglio | Chief Business & Legal Officer and Secretary | 391,638 | 1972 |
| Noel Donnelly | Chief Financial Officer | 742,595 | 1970 |
| Michael Zhao | Vice President & Head of Biometrics | 0 | N/A |
| Hayley Parker | Senior Vice President of Global Regulatory Affairs & Quality | 0 | N/A |
| Emiko Bryant | Senior Vice President of HR & Administration | 0 | N/A |
| Melissa Michaels | Executive Director & Head of Regulatory Affairs CMC | 0 | N/A |
| Pallavi Lonkar | Vice President & Head of Preclinical | 0 | N/A |
| Kasra Kasraian | Chief Technology Officer | 0 | 1967 |
Description
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
